COST-EFFECTIVENESS OF A FIXED DOSE COMBINATION OF ALENDRONATE AND CHOLECALCIFEROL IN THE TREATMENT OF WOMEN WITH OSTEOPOROSIS AT RISK FOR VITAMIN D DEFICIENCY

被引：0
|
作者：
Ghosh, Sabyasachi [1 ]
Fan, Tao [2 ]
Modi, Ankita [2 ]
Jansen, Jeroen [1 ]
Sen, Shuvayu [2 ]
机构：
[1] MapiValues, Clin & Econ Evidence, Boston, MA USA
[2] Merck & Co Inc, Global Hlth Outcomes, Whitehouse Stn, NJ USA
来源：
OSTEOPOROSIS INTERNATIONAL | 2011年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：132 / 133
页数：2
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD
    Chan, Ming-Cheng
    Tan, Elise Chia-Hui
    Yang, Ming-Chin
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018, 13 : 1079 - 1088
  • [32] Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium
    Gielen, Evelien
    Aldven, Martina
    Kanis, John A.
    Borgstrom, Fredrik
    Senior, Emmanuelle
    Willems, Damon
    OSTEOPOROSIS INTERNATIONAL, 2024, 35 (07) : 1173 - 1183
  • [33] Cost for original fixed combination from alendronate and vitamin D now on a generic level
    不详
    ZEITSCHRIFT FUR ORTHOPADIE UND IHRE GRENZGEBIETE, 2007, 145 (01): : 16 - 16
  • [34] Cost-Effectiveness of Sequential Abaloparatide/Alendronate for US Women and Men With Osteoporosis and a Recent Vertebral Fracture
    Hiligsmann, Mickael
    Silverman, Stuart
    Singer, Andrea J.
    Pearman, Leny
    Wang, Yamei
    Caminis, John
    Reginster, Jean-Yves
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2023, 30 (12): : 1257 - 1258
  • [35] COST-EFFECTIVENESS OF SEQUENTIAL TREATMENT WITH ABALOPARATIDE FOLLOWED BY ALENDRONATE VS. ALENDRONATE MONOTHERAPY FOR USA WOMEN AT INCREASED RISK OF FRACTURE
    Hiligsmann, M.
    Williams, S. A.
    Fitzpatrick, L. A.
    Silverman, S.
    Weiss, R.
    Reginster, J. -Y.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S503 - S504
  • [36] COST-EFFECTIVENESS OF BINOSTO (BUFFERED SOLUBLE ALENDRONATE 70 MG) EFFERVESCENT TABLET FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN ITALY
    Hiligsmann, M.
    Maggi, S.
    Veronese, N.
    Sartori, L.
    Reginster, J. Y.
    VALUE IN HEALTH, 2020, 23 : S594 - S594
  • [37] COST-EFFECTIVENESS OF BINOSTO (BUFFERED SOLUBLE ALENDRONATE 70 MG) EFFERVESCENT TABLET FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN ITALY
    Hiligsmann, M.
    Maggi, S.
    Onder, G.
    Galluzzo, L.
    Reginster, J. -Y.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S58 - S58
  • [38] COST-EFFECTIVENESS OF DENOSUMAB COMPARED WITH GENERIC ALENDRONATE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROTIC WOMEN
    Hiligsmann, Mickael
    Reginster, Jean-Yves
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : 112 - 113
  • [39] COST-EFFECTIVENESS OF DENOSUMAB COMPARED WITH GENERIC ALENDRONATE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROTIC WOMEN
    Hiligsmann, M.
    Reginster, J. Y.
    VALUE IN HEALTH, 2010, 13 (07) : A309 - A310
  • [40] Lifetime cost-effectiveness of rosiglitazone/metformin fixed dose combination for the treatment of type 2 diabetes in Portugal
    Taylor, M.
    Shearer, A.
    Bagust, A.
    Vaz, J. P.
    Pereira, J.
    DIABETES, 2006, 55 : A548 - A548
12345